Croda International Plc operates in the Pharmaceutical preparations sector. In addition to historical fundamental analyses, the complete report available to purchase compares Croda International Plc with three other companies in this sector in the United Kingdom: Hikma Pharmaceuticals PLC (2018 sales of £1.56 billion [US$2.01 billion] of which 40% was Injectable Pharmaceuticals), Indivior Plc (£755.36 million [US$970.90 million] of which 100% was Buprenorphine Based Drugs), and BTG Plc (£620.50 million [US$797.56 million] of which 39% was Interventional Medicine).

Sales Analysis. Croda International Plc reported sales of £1.39 billion (US$1.78 billion) for the year ending December of 2018. This represents a very small increase of 1.0% versus 2017, when the company's sales were £1.37 billion. This was the fourth straight year of sales growth at Croda International Plc. Sales of Personal Care saw an increase that was more than double the company's growth rate: sales were up 4.5% in 2018, from £466.60 million to £487.80 million. Not all segments of Croda International Plc experienced an increase in sales in 2018: sales of Industrial Chemicals fell 6.9% to £118.20 million. Croda International Plc also experienced decreases in sales in Performance Technologies (down 0.1% to £456.40 million) .